Sakane Yuri, Yamaguchi Masahiko, Shiraishi Atsushi
Department of Ophthalmology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan.
Ehime Prefectural Central Hospital, Matsuyama, Ehime 790-0024, Japan.
J Ophthalmol. 2019 May 2;2019:8145731. doi: 10.1155/2019/8145731. eCollection 2019.
The Dry Eye-Related Quality-of-Life Score (DEQS) is a Japanese dry eye-specific questionnaire that has been used to assess the symptoms of dry eye and their effects on the quality of life (QOL) in Japanese individuals. The purpose of this study was to determine the effect of rebamipide (RBM) on the QOL of Japanese patients with dry eye disease (DED).
The medical records of 43 patients (3 men and 40 women; mean age: 64 ± 14 years; range: 32 to 83 years), who were diagnosed with DED and treated with RBM at the Ehime University Hospital between November 2012 and June 2016, were reviewed. The effects of 2% rebamipide (RBM) ophthalmic suspension on the symptoms of DED was determined by the answers to the DEQS questionnaire and clinical findings. The clinical findings before and 1, 3, 6, 12, and 24 months after initiating the RBM treatment were reviewed. The following data were collected from the DEQS: the Summary score and two subscale scores, the Bothersome ocular symptoms score, and the Impact on daily life score. In addition, the standard fluorescein staining score, the Schirmer I test score, and the tear breakup time (TBUT) score were analyzed.
The Summary score and Impact of daily life score of the DEQS were improved significantly after 1, 3, 6, and 12 months of RBM, and the Bothersome ocular symptoms scores of the DEQS were also improved after 1, 3, and 6 months. The fluorescein staining scores were significantly decreased after 1, 3, 6, and 12 months, and the TBUT score was significantly increased after 1 month.
RBM treatment improves the QOL by alleviating the corneal and conjunctival epithelial damages. The DEQS is a useful questionnaire that can assess the severity of the DED symptoms and their impact on the QOL. This trial is registered with UMIN000024405.
干眼相关生活质量评分（DEQS）是一份日本的干眼特异性问卷，已用于评估日本人群的干眼症状及其对生活质量（QOL）的影响。本研究的目的是确定瑞巴派特（RBM）对日本干眼疾病（DED）患者生活质量的影响。
回顾了2012年11月至2016年6月期间在爱媛大学医院被诊断为DED并接受RBM治疗的43例患者（3例男性和40例女性；平均年龄：64±14岁；范围：32至83岁）的病历。通过DEQS问卷的答案和临床检查结果确定2%瑞巴派特（RBM）眼用混悬液对DED症状的影响。回顾了开始RBM治疗前以及治疗后1、3、6、12和24个月的临床检查结果。从DEQS中收集以下数据：总分和两个子量表分数、烦人的眼部症状分数以及对日常生活的影响分数。此外，还分析了标准荧光素染色分数、Schirmer I试验分数和泪膜破裂时间（TBUT）分数。
RBM治疗1、3、6和12个月后，DEQS的总分和对日常生活的影响分数显著改善，DEQS的烦人的眼部症状分数在1、3和6个月后也有所改善。荧光素染色分数在1、3、6和12个月后显著降低，TBUT分数在1个月后显著增加。
RBM治疗通过减轻角膜和结膜上皮损伤来改善生活质量。DEQS是一份有用的问卷，可评估DED症状的严重程度及其对生活质量的影响。本试验已在UMIN000024405注册。
